Fresenius stock sits 0.78 percent below Xetra close at EUR 45.08
Published on 10/18/2026 at 17:58 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSAcquisition and reporting dates
- Fresenius announced the acquisition of mAbxience on October 1, 2026, for up to EUR 750 million.
- Fresenius stock trades at EUR 44.73 at 5:56 p.m. CEST on October 18, 2026, 0.78 percent below the Xetra close of October 16, 2026, at EUR 45.08.
- Fresenius lists November 4, 2026, for its third-quarter 2026 conference call.
Fresenius stock was at EUR 44.73 in weekend trading at Lang & Schwarz at 5:56 p.m. CEST on October 18, 2026, 0.78 percent below the Xetra close of EUR 45.08 on October 16, 2026. Fresenius had announced the acquisition of the remaining 45 percent of mAbxience for up to EUR 750 million on October 1, 2026, according to the company’s press release.
Market context: Market report DAX.
The week in figures
The Xetra close used for the weekly comparison was EUR 45.08 on October 16, 2026. The Lang & Schwarz weekend price was EUR 44.73 at 5:56 p.m. CEST on October 18, 2026, which was 0.78 percent below that reference level.
The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Fresenius stock.
mAbxience acquisition
Fresenius said on October 1, 2026, that it acquired the remaining 45 percent of mAbxience from Insud Pharma and Invim Corporativo. The transaction was signed and completed on September 30, 2026, and required no regulatory approvals. The consideration includes a contingent payment of EUR 50 million tied to site approvals, while Fresenius said no new financing was required. The company’s release states that the transaction did not change its full-year 2026 guidance. These details are set out in the company release.
Dates ahead
Fresenius’s investor-relations page lists November 4, 2026, for its third-quarter 2026 conference call. The date appears on the company’s investor-relations page.
